ArticlePhysiology & behavior2017
The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc).
Article in Physiology & behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Amylin: A Multi-Functional Pancreatic Hormone-A Review.Diabetes, obesity & metabolism · 2026Review
- Brain Amylin Signaling, Feeding, and Reward.Comprehensive Physiology · 2026Review
- The story of amylin: from physiology to therapy.Nature metabolism · 2026Review
- Overview of the therapeutic efficacy of marine fish oil in managing obesity and associated metabolic disorders.Physiological reports · 2024Review
- Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights.Physiology & behavior · 2023Review
- Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards.Addiction neuroscience · 2022Article
- Mediators of Amylin Action in Metabolic Control.Journal of clinical medicine · 2022Review
- Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances.Biomolecules · 2021Review
- Fluid intake, what's dopamine got to do with it?Physiology & behavior · 2021Article
- Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.Molecular metabolism · 2021Review
- Salmon Calcitonin Attenuates Some Behavioural Responses to Nicotine in Male Mice.Frontiers in pharmacology · 2021Article
- Effects of sub-chronic amylin receptor activation on alcohol-induced locomotor stimulation and monoamine levels in mice.Psychopharmacology · 2020Article
- Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents.Addiction biology · 2019Article
- Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.Molecular metabolism · 2018Review
- Parallels and Overlap: The Integration of Homeostatic Signals by Mesolimbic Dopamine Neurons.Frontiers in psychiatry · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
The pancreatic hormone amylin and its agonist salmon calcitonin (sCT) act via the area postrema (AP) and the lateral parabrachial nucleus (PBN) to reduce food intake. Investigations of amylin and sCT signaling in the ventral tegmental area (VTA) and nucleus accumbens (NAc) suggest that the eating inhibitory effect of amylin is, in part, mediated through the mesolimbic 'reward' pathway. Indeed, administration of the sCT directly to the VTA decreased phasic dopamine release (DA) in the NAc. However, it is not known if peripheral amylin modulates the mesolimbic system directly or whether this occurs via the AP and PBN. To determine whether and how peripheral amylin or sCT affect mesolimbic reward circuitry we utilized fast scan cyclic voltammetry under anesthesia to measure phasic DA release in the NAc evoked by electrical stimulation of the VTA in intact, AP lesioned and bilaterally PBN lesioned rats. Amylin (50μg/kg i.p.) did not change phasic DA responses compared to saline control rats. However, sCT (50μg/kg i.p.) decreased evoked DA release to VTA-stimulation over 1h compared to saline treated control rats. Further investigations determined that AP and bilateral PBN lesions abolished the ability of sCT to suppress evoked phasic DA responses to VTA-stimulation. These findings implicate the AP and the PBN as important sites for peripheral sCT to decrease evoked DA release in the NAc and suggest that these nuclei may influence hedonic and motivational processes to modulate food intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.